Search results for: 'cdmo market 2026'

CDMOs are third-party vendors that offer outsourced development and manufacturing services for pharmaceutical drugs. In the small molecule manufacturing sector, CDMOs provide expert development and manufacturing services and are now an essential part of the pharmaceutical industry's value chain. The growing incidence of chronic diseases propels t...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

The bio‑CDMO industry is entering an era of accelerated growth driven by the global shift toward complex biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), cell and gene therapies, recombinant proteins, and advanced vaccines. Large molecules are projected to record a 10.3% CAGR between 2025 and 2031, signaling sustained de...

This report provides a definitive strategic roadmap for the digital marketing and advertising technology (AdTech/MarTech) sector as it enters a transformative era in 2026. Moving beyond incremental updates, the industry is undergoing a fundamental architectural restructuring—shifting from a landscape of fragmented point solutions to one of unified ...

The global distribution infrastructure and delivery market is entering a state of hyper-transformation in 2026. This market, which serves as the foundational architecture for the digital economy, has moved beyond the simple, high-speed movement of packets to become the primary orchestrator of digital trust, sovereign data residency, and autonomous ...

The global enterprise landscape is currently navigating a profound era of transformation driven by the Intelligence Revolution. This shift is redefining the fundamental mechanics of how organizations create, manage, and orchestrate content at scale. In 2026, the digital content creation, management, and orchestration sector is moving beyond the sim...

The global pharmaceutical market is projected to reach approximately $1.72 trillion in 2026, with large molecules driving most incremental growth while small molecules remain the sector’s cash flow base. The current growth cycle concentrates on cardiometabolic and oncology, led by GLP-1 platforms and antibody–drug conjugates (ADCs). Competitive adv...

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC rev...

The Healthcare IT Outlook 2026 examines the industry’s transition from experimentation to enterprise-scale execution, as artificial intelligence (AI), workflow orchestration, and platform consolidation reshape clinical, operational, and financial workflows. Following several years of pilot-led innovation, 2026 marks a pivotal inflection point where...